Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Pharmacol ; 788: 98-103, 2016 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-27321871

RESUMO

Topical agents containing vitamin D3 (VD3) analogues such as calcipotriol, maxacalcitol and tacalcitol and the combination of calcipotriol/betamethasone dipropionate (betamethasone) are prescribed for patients with psoriasis. However, they are known to occasionally cause hypercalcemia, and the frequency of hypercalcemia is suggested to vary according to the VD3 analogue used. In this study, to address the reason for these differences, the calcemic effects of maxacalcitol-, calcipotriol- and calcipotriol/betamethasone-containing ointments in rats were evaluated. The serum calcium levels in rats treated with ointments containing maxacalcitol, but not calcipotriol or calcipotriol/betamethasone, were significantly elevated, which is consistent with clinical observations. The serum concentration of VD3 analogue in rats treated with ointments containing calcipotriol and calcipotriol/betamethasone was lower than that in rats treated with maxacalcitol-containing ointment. Thus, the calcemic effects appear to be associated with the systemic exposure of VD3 analogues in rats. To understand the mechanism underlying the different systemic exposures of VD3 analogues, skin permeation and metabolic stability of VD3 analogues were evaluated. The cumulative amount of calcipotriol permeated through rat skin was significantly lower than that of maxacalcitol. On the other hand, the metabolic clearance of calcipotriol in rat hepatocytes was higher than that of maxacalcitol. Similar results were obtained using human skin and human hepatocytes. The current study demonstrates that the lower calcemic effects of calcipotriol- and calcipotriol/betamethasone-containing ointments are caused by the low systemic exposure of calcipotriol according to low skin permeability and rapid hepatic elimination after topical application.


Assuntos
Colecalciferol/análogos & derivados , Colecalciferol/efeitos adversos , Hipercalcemia/induzido quimicamente , Administração Tópica , Animais , Colecalciferol/metabolismo , Colecalciferol/farmacocinética , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Pomadas , Permeabilidade , Ratos , Ratos Sprague-Dawley , Pele/metabolismo
2.
Langmuir ; 28(47): 16430-5, 2012 Nov 27.
Artigo em Inglês | MEDLINE | ID: mdl-23106296

RESUMO

The facile synthesis of an organic electric conducting nanowire is described. The simple oxidation of 9-methylcarbazole by iron(III) perchlorate in a methanol/acetonitrile mixture under atmospheric pressure and temperature produces abundant nanowires without using a template. The nanowire consists of 9,9'-dimethyl-3,3'-dicarbazyl and has a rectangular nanowire shape with an average diameter of 397 ± 50 nm and length of 17 ± 5 µm. The results of the elemental analysis, (1)H NMR, FT-IR, XPS, and ESR measurements revealed that the chemical composition of the nanowire is (dicarbazyl)(0.12)(dicarbazylium·ClO(4)(-))(0.88)·H(2)O. This result, combined with the UV-vis-NIR measurement, demonstrates that 9,9'-dimethyl-3,3'-dicarbazyl stacks in a mixed valence state. The nanowire is electroactive and has an electric conductivity of 3.0 × 10(-5) S cm(-1).

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...